Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective, cross-sectional, diagnostic accuracy study

IF 19.9 1区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Byron W P Reeve PhD, Gcobisa Ndlangalavu PhD, Hridesh Mishra PhD, Zaida Palmer MSc, Happy Tshivhula PhD, Loren Rockman BSc (Hons), Selisha Naidoo MSc, Desiree L Mbu MSc, Charissa C Naidoo PhD, Brigitta Derendinger PhD, Prof Gerhard Walzl MD PhD, Stephanus T Malherbe MD PhD, Prof Paul D van Helden PhD, Fred C Semitala MD, Christina Yoon MD, Rishi K Gupta MRCP PhD, Prof Mahdad Noursadeghi FRCP PhD, Prof Robin M Warren PhD, Prof Grant Theron PhD
{"title":"Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective, cross-sectional, diagnostic accuracy study","authors":"Byron W P Reeve PhD, Gcobisa Ndlangalavu PhD, Hridesh Mishra PhD, Zaida Palmer MSc, Happy Tshivhula PhD, Loren Rockman BSc (Hons), Selisha Naidoo MSc, Desiree L Mbu MSc, Charissa C Naidoo PhD, Brigitta Derendinger PhD, Prof Gerhard Walzl MD PhD, Stephanus T Malherbe MD PhD, Prof Paul D van Helden PhD, Fred C Semitala MD, Christina Yoon MD, Rishi K Gupta MRCP PhD, Prof Mahdad Noursadeghi FRCP PhD, Prof Robin M Warren PhD, Prof Grant Theron PhD","doi":"10.1016/s2214-109x(24)00052-4","DOIUrl":null,"url":null,"abstract":"Tuberculosis, a major cause of death in people living with HIV, remains challenging to diagnose. Diagnostic accuracy data are scarce for promising triage and confirmatory tests such as C-reactive protein (CRP), sputum and urine Xpert MTB/RIF Ultra (Xpert Ultra), and urine Determine TB LAM Ag (a lateral flow lipoarabinomannan [LF-LAM] test), without symptom selection. We evaluated novel triage and confirmatory tests in ambulatory people with HIV initiating antiretroviral therapy (ART). 897 ART-initiators were recruited irrespective of symptoms and sputum induction offered. For triage (n=800), we evaluated point-of-care blood-based CRP testing, compared with the WHO-recommended four-symptom screen (W4SS). For sputum-based confirmatory testing (n=787), we evaluated Xpert Ultra versus Xpert MTB/RIF (Xpert). For urine-based confirmatory testing (n=732), we evaluated Xpert Ultra and LF-LAM. We used a sputum culture reference standard. 463 (52%) of 897 participants were female. The areas under the receiver operator characteristic curves for CRP was 0·78 (95% CI 0·73–0·83) and for number of W4SS symptoms was 0·70 (0·64–0·75). CRP (≥10 mg/L) had similar sensitivity to W4SS (77% [95% CI 68–85; 80/104] 77% [68–85; 80/104]; p>0·99] but higher specificity (64% [61–68; 445/696] 48% [45–52; 334/696]; p<0·0001]; reducing unnecessary confirmatory testing by 138 (95% CI 117–160) per 1000 people and number-needed-to-test from 6·91 (95% CI 6·25–7·81) to 4·87 (4·41–5·51). Sputum samples with Xpert Ultra, which required induction in 49 (31%) of 158 of people (95% CI 24–39), had higher sensitivity than Xpert (71% [95% CI 61–80; 74/104] 56% [46–66; 58/104]; p<0·0001). Of the people with one or more confirmatory sputum or urine test results that were positive, the proportion detected by Xpert Ultra increased from 45% (26–64) to 66% (46–82) with induction. Programmatically done haemoglobin, triage test combinations, and urine tests showed comparatively worse results. CRP is a more specific triage test than W4SS in those initiating ART. Sputum induction improves diagnostic yield. Sputum samples with Xpert Ultra is a more accurate confirmatory test than with Xpert. South African Medical Research Council, EDCTP2, US National Institutes of Health–National Institute of Allergy and Infectious Diseases.","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":null,"pages":null},"PeriodicalIF":19.9000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Global Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2214-109x(24)00052-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis, a major cause of death in people living with HIV, remains challenging to diagnose. Diagnostic accuracy data are scarce for promising triage and confirmatory tests such as C-reactive protein (CRP), sputum and urine Xpert MTB/RIF Ultra (Xpert Ultra), and urine Determine TB LAM Ag (a lateral flow lipoarabinomannan [LF-LAM] test), without symptom selection. We evaluated novel triage and confirmatory tests in ambulatory people with HIV initiating antiretroviral therapy (ART). 897 ART-initiators were recruited irrespective of symptoms and sputum induction offered. For triage (n=800), we evaluated point-of-care blood-based CRP testing, compared with the WHO-recommended four-symptom screen (W4SS). For sputum-based confirmatory testing (n=787), we evaluated Xpert Ultra versus Xpert MTB/RIF (Xpert). For urine-based confirmatory testing (n=732), we evaluated Xpert Ultra and LF-LAM. We used a sputum culture reference standard. 463 (52%) of 897 participants were female. The areas under the receiver operator characteristic curves for CRP was 0·78 (95% CI 0·73–0·83) and for number of W4SS symptoms was 0·70 (0·64–0·75). CRP (≥10 mg/L) had similar sensitivity to W4SS (77% [95% CI 68–85; 80/104] 77% [68–85; 80/104]; p>0·99] but higher specificity (64% [61–68; 445/696] 48% [45–52; 334/696]; p<0·0001]; reducing unnecessary confirmatory testing by 138 (95% CI 117–160) per 1000 people and number-needed-to-test from 6·91 (95% CI 6·25–7·81) to 4·87 (4·41–5·51). Sputum samples with Xpert Ultra, which required induction in 49 (31%) of 158 of people (95% CI 24–39), had higher sensitivity than Xpert (71% [95% CI 61–80; 74/104] 56% [46–66; 58/104]; p<0·0001). Of the people with one or more confirmatory sputum or urine test results that were positive, the proportion detected by Xpert Ultra increased from 45% (26–64) to 66% (46–82) with induction. Programmatically done haemoglobin, triage test combinations, and urine tests showed comparatively worse results. CRP is a more specific triage test than W4SS in those initiating ART. Sputum induction improves diagnostic yield. Sputum samples with Xpert Ultra is a more accurate confirmatory test than with Xpert. South African Medical Research Council, EDCTP2, US National Institutes of Health–National Institute of Allergy and Infectious Diseases.
用于未经选择的抗逆转录病毒疗法启动者结核病筛查和诊断的床旁 C 反应蛋白和 Xpert MTB/RIF Ultra:一项前瞻性横断面诊断准确性研究
结核病是导致艾滋病病毒感染者死亡的一个主要原因,但其诊断仍然具有挑战性。C反应蛋白(CRP)、痰液和尿液 Xpert MTB/RIF Ultra(Xpert Ultra)以及尿液 Determine TB LAM Ag(一种侧流脂联菌素[LF-LAM]检测)等有前途的分诊和确诊检测方法,在没有症状选择的情况下,诊断准确率数据很少。我们对开始接受抗逆转录病毒疗法(ART)的门诊艾滋病病毒感染者进行了新型分诊和确证检验的评估。我们招募了 897 名开始接受抗逆转录病毒疗法的患者,无论其症状如何,是否提供痰液诱导。对于分流(800 人),我们评估了基于血液的床旁 CRP 检测,并与世界卫生组织推荐的四症状筛查(W4SS)进行了比较。对于基于痰液的确证检测(787 人),我们评估了 Xpert Ultra 与 Xpert MTB/RIF (Xpert)。对于尿液确证检验(732 人),我们评估了 Xpert Ultra 和 LF-LAM。我们采用了痰培养参考标准。897 名参与者中有 463 人(52%)为女性。CRP和W4SS症状数量的接收者操作特征曲线下面积分别为0-78(95% CI 0-73-0-83)和0-70(0-64-0-75)。CRP(≥10 mg/L)的敏感性与 W4SS 相似(77% [95% CI 68-85; 80/104] 77% [68-85; 80/104]; p>0-99),但特异性更高(64% [61-68; 445/696] 48% [45-52; 334/696];p<0-0001];每 1000 人中不必要的确证检测减少 138 例(95% CI 117-160 例),检测所需人数从 6-91 例(95% CI 6-25-7-81 例)减少到 4-87 例(4-41-51-51 例)。158 人中有 49 人(31%)(95% CI 24-39)的痰标本需要 Xpert Ultra 诱导检测,其灵敏度高于 Xpert(71% [95% CI 61-80; 74/104] 56% [46-66; 58/104];P<0-0001)。在有一次或多次痰液或尿液确证检测结果呈阳性的人群中,经 Xpert Ultra 检测出的比例从 45% (26-64) 增加到 66% (46-82)。按程序进行的血红蛋白、分诊检验组合和尿液检验的结果相对较差。在开始接受抗逆转录病毒疗法的患者中,CRP 是比 W4SS 更特异的分流检测方法。痰液诱导可提高诊断率。使用 Xpert Ultra 对痰样本进行确诊比使用 Xpert 进行确诊更为准确。南非医学研究委员会、EDCTP2、美国国立卫生研究院-国立过敏与传染病研究所。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lancet Global Health
Lancet Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
44.10
自引率
1.20%
发文量
763
审稿时长
10 weeks
期刊介绍: The Lancet Global Health is an online publication that releases monthly open access (subscription-free) issues.Each issue includes original research, commentary, and correspondence.In addition to this, the publication also provides regular blog posts. The main focus of The Lancet Global Health is on disadvantaged populations, which can include both entire economic regions and marginalized groups within prosperous nations.The publication prefers to cover topics related to reproductive, maternal, neonatal, child, and adolescent health; infectious diseases (including neglected tropical diseases); non-communicable diseases; mental health; the global health workforce; health systems; surgery; and health policy.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信